An interventional study of Standard hypercaloric-hyperproteic nutritional supplementation and HMB-enriched hypercaloric-hyperproteic nutritional supplementation with vitamin D and calcium in Colon Cancer, sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies in Colonic Neoplasms with a site in Spain — 33 open to participants now, 47 under way, 7 of them phase 3. Colonic Neoplasms · Spain.
Among the 121 studies in Colonic Neoplasms with a site in Spain, this one is the 53rd largest by planned enrollment of the 91 interventional ones that give a count, is one of 10 that started in 2025, is one of 25 with no phase, reaches primary completion later than 24 of the 46 other live ones, and was the 118th registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.
Browse Colonic Neoplasms studies →33 of the 121 studies in Colonic Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
Solstice Oncology, Inc. · Sites in Spain, United States, Belgium and 3 more countries
Ages 18+
Blueprint Medicines Corporation · Sites in Spain, United States
Ages 18+
Incyte Corporation · Sites in Spain, United States, Argentina and 19 more countries
Ages 18+
Pfizer · Sites in Spain, United States, France
Ages 18+
Pfizer · Sites in Spain, United States, Argentina and 17 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 33 · Phase 3 17 · Phase 4 2
First in 1998; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.
Median enrollment 155 across the 91 interventional studies, 300 across the 27 observational. Of the 55 that completed or were terminated, 15 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 121 have an industry lead sponsor. The 10 most frequent:
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud is the lead sponsor of 72 studies on the registry; 23 are open to participants now.
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud has 2 studies filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
9 of the studies in Colonic Neoplasms with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06567782GlaxoSmithKlineA Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer | 2026-11-23 |
| NCT07821333Fundación para la Investigación del Hospital Clínico de ValenciaCirculating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II-III | 2027-01-01 |
| NCT05433142Xencor, Inc.Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | 2027-02 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT07534852Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludNIMA-Colon Cancer Study | 2027-08 |
Add all 9 to your calendar (.ics) → With an account.
Among the 121 studies in Colonic Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate the effects of nutritional supplementation and physical activity interventions on recovery, muscle strength, nutritional status, inflammation, and metabolic health in adults with colon cancer undergoing surgery.
Patients with colon cancer frequently experience loss of muscle mass, reduced physical function, and nutritional deterioration both before and after surgery, which may adversely affect recovery and quality of life.
A key objective of this study is to assess whether a postoperative intervention combining nutritional supplementation with beta-hydroxy beta-methylbutyrate (HMB) and vitamin D, together with a structured physical activity program, can improve muscle strength and functional recovery following colon cancer surgery.
This study aims to answer the following questions:
Participants will be adults diagnosed with colon cancer who undergo surgical treatment at the Hospital Universitario Virgen de la Victoria in Málaga, Spain. Patients will be recruited prior to surgery and will enter a prehabilitation phase integrated into routine care provided by the Endocrinology and Nutrition Department.
During this prehabilitation phase, nutritional status will be assessed and optimized using standard clinical care, including oral nutritional supplementation when indicated. The aim is to improve the patient's condition before surgery. Approximately one month after surgery, once initial postoperative recovery has been completed, participants will enter the intervention and assessment phase (baseline visit).
Participants will then be randomly assigned to one of four study groups in a 2×2 factorial design. These groups combine two nutritional strategies (standard care or supplementation with HMB and vitamin D) and two physical activity approaches (supervised exercise or general activity recommendations). The physical activity component, supervised by the Endocrinology and Nutrition team, will be objectively evaluated using an accelerometer-based device. Participants will be followed for approximately six months, with assessments at about 3 and 6 months after the baseline visit.
At each visit, participants will undergo:
The results of this study will contribute to a more profound understanding of how tailored nutritional strategies and postoperative physical activity may support recovery and functional health in patients undergoing surgery for colon cancer.
Colon cancer patients frequently present with nutritional impairment, systemic inflammation, and early loss of muscle mass even before surgical treatment. These conditions may be exacerbated by surgical stress, reduced intake, and postoperative physical inactivity, leading to delayed recovery, functional decline, and impaired quality of life. Interventions targeting nutritional and functional status across the perioperative period may help improve physiological reserve and support postoperative recovery.
The NIMA study (Nutritional, Inflammatory, and Muscular Assessment) is designed to evaluate the impact of perioperative nutritional care and postoperative physical activity strategies on recovery, muscle strength, nutritional status, inflammation, metabolic health, and gut microbiota in adults undergoing surgery for colon cancer. The study combines routine preoperative nutritional management with a structured postoperative intervention and follow-up period, allowing assessment of short- and medium-term changes during recovery.
Study Setting and Population: This study includes adult patients diagnosed with colon cancer stages I to III, (TNM classification) who undergo surgical treatment at the Hospital Universitario Virgen de la Victoria in Málaga, Spain. Participants are identified and recruited before surgery through standard clinical pathways. All participants provide written informed consent before enrollment. The study is conducted in accordance with ethical principles and has been approved by the appropriate ethics committee.
Prehabilitation Phase (Preoperative Nutritional Care): Approximately two weeks before surgery, patients undergo a prehabilitation phase integrated into routine clinical care provided by the Endocrinology and Nutrition Department. This phase includes assessment and optimization of nutritional status through clinical evaluation, follow-up, and oral hypercaloric and hyperproteic supplementation when indicated. The aim is to improve metabolic condition and physiological reserve prior to surgical stress.
Surgical Treatment and Standard Postoperative Care: All participants undergo standard surgical treatment and postoperative oncological management according to institutional clinical practice. Participation in the study does not modify surgical procedures, immediate postoperative care, or oncological treatment.
Postoperative Interventions(Factorial Design): Approximately one month after surgery, once initial postoperative recovery has been achieved, participants enter the intervention phase (baseline visit). Participants are randomly assigned to one of four study groups according to a 2×2 factorial design:
The supervised physical activity program consists of structured, progressive resistance and functional exercises adapted to each participant's postoperative condition, targeting major muscle groups to improve muscle strength and functional capacity. Participants assigned to general physical activity receive standard recommendations according to routine clinical practice. Physical activity levels are objectively assessed using a wearable accelerometer.
Follow-up and Assessments: Approximately one month after surgery, once initial postoperative recovery has been achieved, participants enter the intervention and assessment phase (baseline visit) and are followed for approximately six months, with follow-up assessments at around 3 and 6 months. A comprehensive morphofunctional evaluation is performed at baseline and repeated at 6 months, including body composition, muscle strength, functional performance, and nutritional assessment using techniques such as bioelectrical impedance analysis, nutritional ultrasound, and standardized functional tests. Additional strength and resistance tests are also conducted as part of the study-specific evaluations. Biological samples (blood, urine, and stool) are collected at predefined time points to assess metabolic, inflammatory, and microbiota-related parameters. At the 3-month visit, a partial assessment is carried out, including selected clinical, functional, and questionnaire-based measures(including validated questionnaires assessing health status, quality of life, dietary intake, physical activity levels, and psychological well-being), allowing evaluation of both short- and medium-term changes during postoperative recovery. For participants assigned to the structured and supervised physical activity program, physical activity adherence, intensity, and patterns are objectively monitored using a wearable accelerometer, which is worn for 7 consecutive days monthly throughout the follow-up period, providing quantitative data on real-world physical activity behavior.
Study Relevance: By integrating perioperative nutritional care with structured postoperative interventions within a factorial design, the NIMA study aims to determine the independent and combined effects of nutritional supplementation and physical activity on recovery. The findings may contribute to optimizing perioperative care and improving functional outcomes in patients undergoing colon cancer surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive postoperative standard nutritional care according to routine clinical practice and individualized nutritional assessment. In addition, they participate in a structured supervised exercise program including progressive resistance and functional exercises targeting major muscle groups, adapted to their clinical condition.
Dietary Supplement: Standard hypercaloric-hyperproteic nutritional supplementation · Behavioral: Supervised exercise program
Participants receive postoperative enhanced nutritional supplementation, including beta-hydroxy beta-methylbutyrate (HMB) and vitamin D, in addition to standard nutritional care based on routine clinical practice and individualized nutritional assessment. Participants also receive general physical activity recommendations according to standard postoperative care without participation in a structured exercise program.
Dietary Supplement: HMB-enriched hypercaloric-hyperproteic nutritional supplementation with vitamin D and calcium · Behavioral: General physical activity recommendations
Participants receive postoperative enhanced nutritional supplementation, including beta-hydroxy beta-methylbutyrate (HMB) and vitamin D, in addition to standard nutritional care based on routine clinical practice and individualized nutritional assessment. In addition, they participate in a structured supervised exercise program including progressive resistance and functional exercises targeting major muscle groups, adapted to their clinical condition.
Dietary Supplement: HMB-enriched hypercaloric-hyperproteic nutritional supplementation with vitamin D and calcium · Behavioral: Supervised exercise program
Participants receive postoperative standard nutritional care according to routine clinical practice and individualized nutritional assessment. Participants also receive general physical activity recommendations according to standard postoperative care without participation in a structured exercise program.
Dietary Supplement: Standard hypercaloric-hyperproteic nutritional supplementation · Behavioral: General physical activity recommendations
Participants receive a standard oral nutritional supplementation consisting of a hypercaloric and hyperproteic formula designed to support recovery and nutritional status in patients undergoing surgery.
Also known as: Standard Nutrition
Participants receive an oral hypercaloric and hyperproteic nutritional supplementation enriched with β-hydroxy β-methylbutyrate (HMB) and supplemented with vitamin D and calcium. This formulation is designed to support muscle mass preservation and functional recovery in patients undergoing surgical treatment.
Also known as: Enhanced Nutritional Supplementation
Participants follow a structured and supervised physical activity program including resistance exercises and functional training. Physical activity levels are periodically monitored using wearable activity devices.
Also known as: Supervised Physical Activity
Participants receive general recommendations for physical activity according to routine clinical practice but do not participate in the structured supervised exercise program.
Also known as: General Physical Activity
Change in phase angle (PhA)
Phase angle will be assessed by bioelectrical impedance analysis (BIA) as a bioelectrical marker of nutritional and cellular status. Results will be expressed in degrees.
Time frame: Baseline (first postoperative visit) and 6 months follow-up
Change in quadriceps rectus femoris cross-sectional area
Muscle mass will be assessed using nutritional ultrasound by measuring the cross-sectional area of the quadriceps rectus femoris at a standardized anatomical site (cm²).
Time frame: Baseline (first postoperative visit) and 6 months follow-up
Plasma concentration of inflammatory and metabolic biomarkers measured by multiplex immunoassay
Plasma concentrations of selected biomarkers (including adiponectin, FABP-3, FGF-21, BDNF, IL-6, IL-15, TNF-α, and MCP-1) will be measured using multiplex immunoassay technology (Bio-Plex MAGPIX / Luminex xMAP). Each biomarker will be analyzed as an individual continuous variable and expressed in pg/mL.
Time frame: From baseline (first postoperative visit), 3 months and 6 months follow-up
Percentage of DNA methylation in peripheral blood mononuclear cells (PBMCs)by quantitative PCR
DNA methylation levels will be assessed in peripheral blood mononuclear cells (PBMCs) using bisulfite conversion followed by quantitative PCR. Results will be expressed as the percentage of methylated cytosines at CpG sites.
Time frame: Baseline (first postoperative visit) and 6 months follow-up
Change in urinary oxylipin concentrations by UHPLC-MS/MS
Selected oxylipins, including isoprostanes, prostaglandins, and thromboxane, will be quantified in first-morning urine samples using targeted ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-QqQ-MS/MS). Results will be expressed as concentrations normalized to urinary creatinine (e.g., ng/mg creatinine).
Time frame: Baseline (first postoperative visit) and 6 months follow-up
Change in relative abundance of gut microbiota taxa
Gut microbiota composition will be assessed in stool samples using 16S rRNA gene sequencing. Relative abundance of bacterial taxa will be quantified at different taxonomic levels (e.g., phylum, genus) and expressed as percentages (%) of total sequencing reads per sample.
Time frame: Baseline (first postoperative visit) and 6 months follow-up
Change in health-related quality of life score (EORTC QLQ-C30)
Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores will be calculated according to standard scoring procedures and expressed on a scale from 0 to 100.
Time frame: Baseline (first postoperative visit), 3 months, and 6 months follow-up
Plan to share: Undecided — A decision regarding the sharing of individual participant data (IPD) has not yet been made. The study has received a favorable opinion from the relevant Research Ethics Committee. As described in the participant information and informed consent, data collected in this study are handled under strict confidentiality and in accordance with applicable data protection regulations, and are intended for research purposes within the scope of the project. If IPD is shared in the future, this would occur only in a de-identified format and upon reasonable request for scientific purposes.
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Aug 2027, 25 months after the start.
Of 382 non-industry interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 55. This study's planned 25 months is below that.
Counting every sponsor, half of 404 studies reached it within 30 months; a quarter within 16 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud